Literature DB >> 12801428

Classification and treatment of tardive syndromes.

Hubert H Fernandez1, Joseph H Friedman.   

Abstract

BACKGROUND: Tardive syndromes are a group of delayed-onset abnormal involuntary movement disorders induced by a dopamine receptor blocking agent. There are several phenomenologically distinct types of TS. REVIEW
SUMMARY: The term tardive dyskinesia has been used to refer to the TS that presents with rapid, repetitive, stereotypic movements mostly involving the oral, buccal, and lingual areas. Tardive dystonia can be focal, segmental, or generalized. It commonly affects the face and neck followed by the arms and trunk. It usually results in retrocollis when it involves the neck and trunk arching backwards when it involves the trunk. Tardive akathisia is characterized by a feeling of inner restlessness and jitteriness with an inability to sit or stand still. Other tardive syndromes include tardive tics, myoclonus, tremor, and withdrawal-emergent syndrome. It remains unclear whether tardive parkinsonism truly exists. The only way to prevent TS is to avoid its etiologic agents. Chronic use of dopamine receptor blocking agents should be limited as much as possible to patients with chronic psychoses. In general, for mild TS, reducing the neuroleptic dose, switching to an atypical agent, or discontinuing antipsychotic treatment altogether in the hope of facilitating remission is recommended. For moderate to severe TS, tetrabenazine or reserpine may be the most effective agent. Neuroleptics should be resumed to treat TD in the absence of active psychosis only as a last resort for persistent, disabling, and treatment-resistant TD.
CONCLUSIONS: The severity of the TS and the absolute need for antipsychotic therapy often dictate the treatment approach for this disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801428     DOI: 10.1097/01.nrl.0000038585.58012.97

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  8 in total

1.  Rapid response of disabling tardive dyskinesia to amantadine: a case report.

Authors:  Gaurav Jain
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.

Authors:  Musa U Umar; Aliyu A Isa; Asmaul H Abba
Journal:  Ther Adv Psychopharmacol       Date:  2015-12-14

3.  Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.

Authors:  Kristian Svendsen; Mollie Wood; Erika Olsson; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2017-12-30       Impact factor: 2.953

4.  Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.

Authors:  Luis Ricardo Peroza; Larissa Finger Schaffer; Catiuscia Molz De Freitas; Caroline Queiroz Leal; Mayara Calegaro Ferrari; Marta Maria Frescura Duarte; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2016-05-26       Impact factor: 3.996

5.  Tardive Dystonia.

Authors:  Frank Skidmore; Stephen G Reich
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

6.  Systematic drug repositioning based on clinical side-effects.

Authors:  Lun Yang; Pankaj Agarwal
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

Review 7.  Calcium channel blockers for antipsychotic-induced tardive dyskinesia.

Authors:  Adib Essali; Karla Soares-Weiser; Hanna Bergman; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2018-03-26

8.  An update on tardive dyskinesia: from phenomenology to treatment.

Authors:  Olga Waln; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.